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Bridelia ferruginea is commonly used in traditional Africanmedicine (TAM) for treating various inflammatory conditions. Extracts
from the plant have been shown to exhibit anti-inflammatory property in a number of in vivo models. In this study the influence
of B. ferruginea (BFE) on the production of PGE2, nitrite, and proinflammatory cytokines from LPS-stimulated BV-2 microglia
was investigated. The eﬀects of BFE on cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) protein expressions
were evaluated in LPS-activated rat primary microglia. The roles of NF-κB and MAPK signalling in the actions of BFE were also
investigated. BFE (25–200 μg) inhibited the production of PGE2, nitrite, tumour necrosis factor-α (TNFα), and interleukin-6 (IL-
6) as well as COX-2 and iNOS protein expressions in LPS-activated microglial cells. Further studies to elucidate the mechanism
of anti-inflammatory action of BFE revealed interference with nuclear translocation of NF-κBp65 through mechanisms involving
inhibition of IκB degradation. BFE prevented phosphorylation of p38, but not p42/44 or JNK MAPK. It is suggested that Bridelia
ferruginea produces anti-inflammatory action through mechanisms involving p38 MAPK and NF-κB signalling.
1. Introduction
Traditional African medicine (TAM) is a shorthand reference
to indigenous forms of healing that are practiced all over
Africa [1]. Bridelia ferruginea Benth. (Euphorbiaceae) is a
shrub which is employed in TAM for treating arthritis and
as an embrocation for the treatment of bruises, boils, dislo-
cation, and burns [2, 3]. Tea made from the pulped bark is
used for fevers, headaches, stiﬀness, and rheumatic pains and
as a local application for treating oedemas [4]. Earlier, we
observed that the aqueous extract of B. ferruginea stem
bark exhibited inhibition of both the carrageenan-induced
rat paw oedema and cotton pellet granuloma formation in
rats [5]. Topical anti-inflammatory, antiarthritic, antipyretic,
and analgesic properties of the plant were also reported
by us [6]. We also showed that a stem bark extract of B.
ferruginea protected mice from lipopolysaccharide- (LPS-)
induced septic shock and inhibited LPS-induced vascular
permeability [7]. Recently, Akuodor et al. [8] reported that
a stem bark extract of B. ferruginea exhibited potential
analgesic and antipyretic properties inmice and rats. Extracts
from the plant have been reported to demonstrate in vitro
antioxidant activity in the DPPH free radical scavenging
assay [9]. In spite of the varied ethnopharmacological
applications of B. ferruginea in inflammatory conditions and
its demonstrated actions in vivo, to our knowledge there is no
documented evidence of the molecular target(s) of its anti-
inflammatory actions.
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Cyclooxygenase (COX) is an enzyme that is required for
the synthesis of prostaglandins. There are two subtypes of
this enzyme: cyclooxygenase-1 (COX-1) and cyclooxygenase-
2 (COX-2). COX-1 is expressed constitutively in most cell
types, whereas expression of COX-2 is induced by various
factors including inflammatory cytokines and is responsible
for the maintenance of the inflammatory process.
Nuclear factor-kappa B (NF-κB) is a transcription fac-
tor which has been considered to be the critical central
regulator of the inflammatory process. NF-κB controls the
expression of genes encoding the proinflammatory cytokines
(IL-6, TNFα, IL-1, IL-2, etc.), chemokines (IL-8, mcp-
1, RANTES, etc.), adhesion molecules (ICAM, VCAM, E-
selectin), inducible enzymes (COX-2 and iNOS), growth
factors, some acute phase proteins, and immune recep-
tors, all of which play critical roles in controlling major
inflammatory processes [10]. NF-κB has therefore become
a critical molecular target in drug discovery, and several
natural and synthetic compounds have been investigated for
their potential to inhibit NF-κB [11].
The mitogen-activated protein (MAP) kinases are intra-
cellular enzymes which allow cells to respond to stimuli such
as inflammatory cytokines, from their extracellular envi-
ronment [12]. MAPKs include extracellular signal-regulated
kinases (ERK 1/2), c-Jun N-terminal kinases (JNKs) and
p38 isoforms. p38 MAPK pathway has been shown to play
a central role in the expression and activity of proinflam-
matory cytokines such as TNFα, IL-6, IL-7, and IL-8 in
many cell types [13]. Evidences supporting the importance
of the p38 MAPK in inflammatory diseases, such as asthma,
rheumatoid arthritis, systemic inflammation, inflammatory
bowel disease, and brain inflammation, have been reviewed
by Yong et al. [13].
In this study we have used cellular models of CNS inflam-
mation to show that a stem bark extract of B. ferruginea
(BFE) produces antineuroinflammatory action through inhi-
bition of steps in the signalling of NF-κB and p38 MAPK.
2. Materials and Methods
2.1. Plant Material. Bridelia ferruginea stem bark was col-
lected from a tree growing on the University of Ibadan
Campus, Nigeria. The plant samples were identified in the
Herbarium, Botany Department, University of Ibadan as well
as the Herbarium, Forestry Research Institute of Nigeria,
Ibadan, Nigeria. These samples were authenticated using
voucher specimens deposited at various periods. A voucher
specimen of the collected plant samples was also deposited in
the FRIN herbarium, and given the specimen number F.H.I.
106501. The stem bark was air-dried at room temperature,
powdered, and extracted in a mixture of methanol and water
(1 : 1) for 24 h. The resulting extract was further extracted for
additional 24 h. The extract was filtered and concentrated in
vacuo at 24◦C.
2.2. Cell Culture. Primary mixed glial cell cultures were
established from cerebral cortices of one-day neonatal
Sprague-Dawley rats as described earlier [14, 15]. Forebrains
were minced and gently dissociated by repeated pipetting in
PBS and filtered through a 70 μM cell strainer (Falcon). Cells
were collected by centrifugation (1000 g, 10min), resus-
pended in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum (Biochrom AG, Berlin,
Germany) and antibiotics (40U/mL penicillin and 40 lg/mL
streptomycin PAA Laboratories, Coelbe, Germany), and
cultured on 10 cm cell culture dishes (5 × 105 cells/plate) in
5% CO2 at 37◦C. Floating microglia were harvested every
week (between 2 and 7 weeks) and reseeded into 75 cm2
culture flask to give pure microglial cultures. The following
day, cultures were washed to remove nonadherent cells, and
freshmediumwas added. The purity of themicroglial culture
was >98% as previously determined by immunofluorescence
and cytochemical analysis [14].
BV-2 mouse microglia cell line ICLC ATL03001 (Interlab
Cell Line Collection, Banca Biologica e Cell Factory, Italy)
was cultured in RPMI 1640 (Gibco) supplemented with 10%
FBS (Sigma), 2mM glutamine (Sigma). Cells were split 1 : 5
when they reached confluence using trypsin/EDTA solution
in PBS.
The human neuroblastoma (SK-N-SH) cells were obtain-
ed from the HPA Culture Collection (Salisbury, UK) and
were grown in MEM-Eagle’s medium (Life Technologies,
UK), which does not contain any anti-inflammatory sub-
stance. Medium was supplemented with 5% foetal bovine
serum (Sigma, UK), 2mM L-glutamine, 1mM sodium
pyruvate, and 40 units/mL penicillin/streptomycin (Sigma,
UK). Confluent monolayers were passaged routinely by
trypsinisation. Cultures were grown at 37◦C in 5%CO2 until
80% confluence, and themediumwas changed the day before
treatment.
2.3. PGE2 Enzyme Immunoassay (EIA). Quantification of
PGE2 accumulation was carried out in BV-2 cells by seeding
in 96-well plates (2 × 105/200 μL/well), cultured for 2
days, and incubated with or without LPS (100 ng/mL) in
the absence or presence of BFE (25–200 μg/mL) for 24 h.
PGE2 concentration was assessed in cell supernatants with
a commercially available kit (Arbor Assays, Ann Arbor, MI,
USA), followed bymeasurement at 450 nmwith a microplate
reader. Experiments were performed at least three times and
in triplicate.
2.4. Nitrite Assay. Quantification of nitrite accumulation
in BV-2 cells was carried out as described earlier [16].
Cells were seeded in 96-well plates (2 × 105/200 μL/well),
cultured for 2 days, and then incubated with or without
LPS (100 ng/mL) in the absence or presence of BFE (25–
200 μg/mL) for 24 h. As a parameter of NO production,
nitrite concentration was assessed in cell supernatants using
the Griess assay with a commercially available kit (Promega,
SouthamptonUK), followed bymeasurement at 540 nmwith
a Tecan F50 microplate reader. Nitrite concentrations in the
supernatants were determined by comparison with a sodium
nitrite standard curve. Experiments were performed at least
three times and in triplicate.
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Figure 1: Reduction of PGE2 production in LPS-stimulated
microglia. Cells were stimulated with LPS (100 ng/mL) in the pres-
ence or absence of BFE (25–200 μg/mL) for 24 h. At the end
of the incubation period, supernatants were collected for PGE2
measurement. All values are expressed as mean ± SEM for 3
independent experiments. Data were analysed using one-way
ANOVA for multiple comparison with post-hoc Student Newman-
Keuls test. ∗P < 0.05 in comparison with LPS control.
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Figure 2: Reduction of nitrite production in LPS-stimulated mic-
roglia. Cells were stimulated with LPS (100 ng/mL) in the presence
or absence of BFE (25–200 μg/mL) for 24 h. At the end of the incu-
bation period, supernatants were collected for nitrite measurement
with the Griess assay. All values are expressed as mean ± SEM
for 3 independent experiments. Data were analysed using one-way
ANOVA for multiple comparison with post-hoc Student Newman-
Keuls test. ∗P < 0.05 in comparison with LPS control.
2.5. Cytokine ELISA. BV-2 cells were seeded in 96-well plates
(2 × 105/200 μL/well), cultured for 2 days, and incubated
with or without LPS (100 ng/mL) in the absence or presence
of BFE (25–200 μg/mL) for 24 h. TNFα and IL-6 concentra-
tions in supernatants were measured with a commercially
available mouse TNFα and IL-6 ELISA kits (BioLegend Inc.,
San Diego), followed by measurements in a plate reader at
540 nm.
2.6. Immunoblotting. Primary microglia were left untreated
or treated with LPS (100 ng/mL) in the presence or absence of
BFE (25–200 μg/mL) for 24 h. At the end of each experiment,
cells were washed with phosphate-buﬀered saline (PBS)
and lysed in 1.3x sodium-dodecyl-sulfate- (SDS-) contain-
ing sample buﬀer without 1, 4-dithio-dl-threitol (DTT)
or bromophenol blue containing 100 μM orthovanadate.
Protein contents were measured using the bicinchoninic acid
(BCA) method (Pierce Protein Biology), according to the
manufacturer’s instructions. Bovine serum albumin (BSA,
Sigma) was used as a standard. Before electrophoresis, a
mixture of bromophenol blue and DTT (final concentration,
10mM) was added to the samples. For western blotting,
40 μg of total protein from each sample was subjected to SDS-
PAGE (polyacrylamide gel electrophoresis) under reducing
conditions. Proteins were then transferred onto polyvinyli-
dene fluoride (PVDF) membranes (Millipore, Bedford, MA,
USA) by semidry blotting. The membranes were blocked
for 2 hours at room temperature using Rotiblock (Roth,
Karlsruhe, Germany) or nonfat dry milk blotting grade
blocker (Biorad, USA) and incubated overnight with pri-
mary antibodies. Primary antibodies used were goat anti-
COX-2 (Santa Cruz; 1 : 500) and rabbit anti-iNOS (Cell
Signalling; 1 : 1000). Primary antibodies were diluted in Tris-
buﬀered saline (TBS) containing 0.1% Tween 20 (TBS-T)
and 1% BSA. After extensive washing (three times for 15min
each in TBS-T), COX-2 and iNOS proteins were detected
with horseradish peroxidase-coupled rabbit anti-goat IgG
(Santa Cruz, 1 : 100,000 dilution) using chemiluminescence
(ECL) reagents (Amersham Pharmacia Biotech, Freiburg,
Germany). Equal protein loading and transfer were assessed
by subjection of each sample to a western blot for actin
(rabbit antiactin IgG, diluted 1 : 5000). All western blot
experiments were carried out at least three times.
2.7. ELISA for NF-κBp65. SK-N-SH cells were stimulated
with IL-1β (10 units/mL) in the presence or absence of
BFE (25–200 μg/mL) for 1 h. After the stimulation period,
nuclear extracts were prepared using Cayman nuclear extrac-
tion kit (Cayman Chemical Company, Ann Arbor, USA)
according to the manufacturer’s instructions. Briefly, cells
were collected by scraping and washed twice with cold PBS.
Cells were centrifuged for 5min at 4◦C, the supernatant was
discarded, and cell pellet was resuspended in 5mL of ice-
cold PBS. The centrifugation procedure was repeated twice
and the cell pellets were placed on ice and allowed to swell in
500 μL of 1x hypotonic buﬀer, followed by addition of 10%
NP-40 with gentle mixing. The suspension was centrifuged
and the supernatants which contained the cytosolic fractions
were stored at −80◦C for subsequent analysis of cytoplasmic
NF-κB. The pellet was resuspended in 100 μL of ice-cold
complete nuclear extraction buﬀer, vortexed, and rocked
gently for 15min. The samples were then centrifuged and the
supernatants (nuclear fractions) were collected. Cytoplasmic
and nuclear fractions were measured for levels of NF-κB
using human NF-κBp65 ELISA kit (Invitrogen, California,
USA), according to the manufacturer’s instructions.
2.8. ELISA for IκB Degradation. SK-N-SH cells were left
untreated or treated with IL-1β (10 units/mL) in the presence
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Figure 3: Reduction of TNFα ((a) and (b)) and IL-6 ((a) and (c)) production in LPS-stimulated BV-2 microglia. Cells were stimulated with
LPS (100 ng/mL) in the presence or absence of BFE (25–200 μg/mL) for 24 h. At the end of the incubation period, supernatants were collected
for TNFα and IL-6 measurement according to the manufacturer’s instructions. All values are expressed as mean ± SEM for 3 independent
experiments. Data were analysed using one-way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test. ∗P < 0.05 in
comparison with LPS control.
or absence of BFE (25–200 μg/mL) for 30min. At the end of
the stimulation period, cells were washed with phosphate-
buﬀered saline (PBS) and lysed with commercially available
lysis buﬀer (New England Biolabs, UK). Cell lysates were
subjected to human total IκB ELISA according to the
manufacturer’s instructions (R&D Systems, Abingdon, UK).
Concentrations of total IκB in cell lysates were thenmeasured
with a plate reader at 450 nm.
2.9. Sandwich ELISA for MAPK Activity. BV-2 microglia
were left untreated or treated with LPS (100 ng/mL) in the
presence or absence of BFE (25–200 μg/mL) for 30min. At
the end of the stimulation period, cells were washed with
phosphate-buﬀered saline (PBS) and lysed as described
for western blot. Cell lysates were subjected to PathScan
MAP Kinase Multi-Target Sandwich ELISA for phospho-
p38, phospho-42/44, and phospho-JNK according to the
manufacturer’s instructions (Cell Signalling Technologies).
Absorbance values were measured with a plate reader at
450 nm.
2.10. MTT Assay for Cell Viability. The viabilities of rat
primary microglia and BV-2 microglia after treatment with
BFE were determined by the colorimetric 3-(4, 5-dimeth-
ylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)
assay. The yellow compound MTT is reduced by mitochon-
drial dehydrogenases to the water-insoluble blue compound
formazan, depending on the viability of cells. Primary
microglia and BV2microglia were incubated with or without
LPS (100 ng/mL) in the absence or presence of BFE (25–
200 μg/mL) for 24 h. Twenty microlitres of MTT solution
(Sigma) (5mg/mL) was added to each well. The plate was
incubated for 4 h at 37◦C in a CO2-incubator. One hund-
red and eighty microlitres of medium was removed from
every well without disturbing the cell clusters. A 180 μL
methanol/DMSO solution (50 : 50) was added to each well,
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Figure 4: (a) BFE inhibited COX-2 protein expression in LPS-stimulated primary microglia. Cells were stimulated with LPS (100 ng/mL)
in the presence or absence of BFE (25–200 μg/mL) for 24 h. At the end of incubation period, COX-2 protein levels were measured using
western blot using specific antibodies for each protein. (b) Quantitative densitometric analysis of COX-2 protein expression normalized to
actin loading control. All values are expressed as mean ± SEM for 3 independent experiments. Data were analysed using one-way ANOVA
for multiple comparison with post-hoc Student Newman-Keuls test. ∗P < 0.05 in comparison with LPS control.
and the preparations were mixed thoroughly on a plate
shaker with the cell containing formazan crystals. After all
of the crystals were dissolved, the absorbance was read at
540 nm with a microplate reader.
2.11. Statistical Analysis. Values of all experiments were rep-
resented as mean ± SEM of at least 3 experiments. Values
were compared using t-test (two groups) or one way ANOVA
with post-hoc Student Newman-Keuls test (multiple com-
parisons). The level of significance was set at P < 0.05.
3. Results and Discussion
3.1. BFE Reduced PGE2, Nitrite, and Proinflammatory Cyto-
kine Production from LPS-Stimulated Microglia. Following
release from activated microglia, NO, PGE2, and proinflam-
matory cytokines such as TNFα have been implicated as
important mediators in the processes of central nervous
system (CNS) inflammation, which is associated with neu-
rodegenerative diseases [17]. To investigate whether BFE
interferes with these mediators, experiments were carried
out to determine its eﬀects on their production in LPS-
stimulated BV-2 microglia. Cells were pre-treated with BFE,
followed by stimulation with LPS (100 ng/mL) for 24 h.
Results show that incubation of cells with LPS alone for
24 h resulted in an increase in PGE2 level in supernatants
(Figure 1). However, pretreatment with BFE (25–200 μg/mL)
prior to LPS stimulation resulted in significant (P < 0.05)
reduction in PGE2. A similar trend was observed with
supernatants analysed for nitrite production using the Griess
assay (Figure 2) and ELISA measurements for TNFα and
IL-6 (Figures 3(a) and 3(b)). The highest concentration of
BFE used in this experiments (200 μg/mL) reduced PGE2,
nitrite, TNFα, and IL-6 production in LPS-stimulated BV-2
microglia by 51.6, 45, 32.2, and 44.7%, respectively,
demonstrating that BFE strongly inhibits these factors in
LPS-induced neuroinflammation. Although B. ferruginea has
been widely reported to exhibit anti-inflammatory eﬀects in
vivo [5–7], the exact mechanism(s) involved were unknown.
Our current results show that inhibition of PGE2, nitric
oxide, and the proinflammatory cytokines plays significant
roles in the earlier observed in vivo actions of B. ferruginea.
A cell viability assay carried out at the same time revealed
that BFE did not aﬀect viability of BV-2 microglia at
concentrations which produced reductions in PGE2, nitrite
and cytokines produced from the cells (data not shown).
3.2. BFE Eﬀects Are Mediated through Inhibition of COX-
2 and iNOS Protein Expression. Following our observation
that BFE produced marked eﬀects on PGE2 and NO, we
hypothesised that it might be targeting NF-κB, and thus
interfere with the transcription of NF-κB-regulated genes
like COX-2 and iNOS [18]. Western blot experiments were
carried out to investigate the eﬀects of BFE on COX-2 and
iNOS proteins. Rat primary microglia cells were stimulated
with LPS (100 ng/mL) for 24 h; this was followed by a
marked increase in COX-2 protein. Results showed that
BFE produced a dose-dependent and significant (P < 0.05)
reduction in COX-2 protein immunoreactivity induced by
LPS (Figure 4).
Experiments also showed that BFE produced a dose-
dependent and significant inhibition of iNOS protein expres-
sion in LPS-stimulated primary microglia (Figure 5). These
results are consistent with and confirm that the reduction
in PGE2 and NO production by BFE are mediated through
the inhibition of COX-2 and iNOS protein expressions,
respectively.
3.3. BFE Interferes with Nuclear Translocation of NF-κBp65.
On dissociating from IκB, NF-κB moves to the nucleus
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Figure 5: (a) BFE inhibited iNOS protein expression in LPS-
stimulated primary microglia. Cells were stimulated with LPS
(100 ng/mL) in the presence or absence of BFE (25–200 μg/mL)
for 24 h. At the end of incubation period, iNOS protein levels
were measured using western blot using specific antibodies for each
protein. (b) Quantitative densitometric analysis of iNOS protein
expression normalized to actin loading control. All values are
expressed as mean ± SEM for 3 independent experiments. Data
were analysed using one-way ANOVA for multiple comparison with
post-hoc Student Newman-Keuls test. ∗P < 0.05 in comparison
with LPS control.
to trigger the expression of multiple proinflammatory genes,
including COX-2 and iNOS. To further investigate whether
BFE interfered with nuclear translocation of NF-κB, we
employed an ELISA to measure cytoplasmic and nuclear
levels of the p65 subunit of NF-κB in SK-N-SH cells, in the
presence and absence of the extract. IL-1β treatment caused
a marked reduction in cytosolic, and an increase in nuclear
p65 levels when compared with unstimulated cells (Figure 6).
However, pretreatment with BFE (25–200 μg/mL) resulted in
a statistically significant (P < 0.05) increase in cytosolic and
decrease in nuclear NF-κBp65, thereby eﬀectively inhibiting
nuclear translocation of the subunit from the cytoplasm to
the nucleus. In this experiment, parthenolide (20 μM) was
used as reference compound. Parthenolide is a known NF-
κB inhibitor which acts by targeting IκB kinase complex [19,
20] and has been shown to inhibit inflammatory mediators
such as IL-6, TNFα, IL-1β, IL-12 [21], PGE2 [22, 23],
and NO/iNOS [24] in various cells. Parthenolide exhibited
the strongest inhibition of NF-κB activation against IL-1β-
induced NF-κB activation and nuclear translocation in this
experiment.
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Figure 6: BFE inhibited IL-1β-induced nuclear translocation of
NF-κB. SK-N-SH cells were stimulated with IL-1β in the presence
or absence of BFE (25–200 μg/mL) for 1 hour. Cell lysates (nuclear
and cytoplasmic extracts) were then analysed for total NF-κB using
human NF-κBp65 ELISA kit. All values are expressed as mean
± SEM for 3 independent experiments. Optical densities were
measured at 450 nm with a microplate reader. Data were analysed
using one-way ANOVA for multiple comparison with post-hoc
Student Newman-Keuls test. ∗,#P < 0.05 in comparison with IL-1β
control.
3.4. BFE Interferes with NFκB by Inhibiting IκB Degradation.
To further understand the molecular mechanism of action
of BFE, and to investigate the role of IκB in its actions,
we evaluated its action on IκB degradation in SK-N-SH
neuroblastoma cells. IL-1β resulted in complete degradation
of IκBα in these cells. BFE (50–200 μg/mL) significantly
(P < 0.05) blocked IL-1β-induced degradation of IκBα
(Figure 7), indicating that the subsequent inhibition of NF-
κB activation was due to the influence of BFE on IκBα by
BFE. Parthenolide (20 μM) almost completely reversed LPS-
induced degradation of IκB in SK-N-SH cells.
3.5. BFE Inhibited LPS-Induced Phosphorylation of p38, but
Not p42/44 and JNK. p38 MAP kinase (MAPK) participates
in a signalling cascade controlling the cellular response
to proinflammatory cytokines and a variety of cellular
stresses. The p38 MAPK signalling has also been widely
accepted as a cascade contributing to neuroinflammation
[12]. ERK and p38 MAPK cascades have been reported to
contribute to regulation of iNOS and TNFα gene expression
in LPS-activated glial cells [25]. We therefore investigated
whether anti-inflammatory eﬀects of BFE might be related
to the inhibition of MAPK phosphorylation in BV-2 cells
activated with LPS. Results show that LPS treatment caused
marked phosphorylation of p38, p42/44, and JNK MAP
kinases (Figure 8) in BV-2 cells. Pretreatment with BFE did
not produce significant eﬀects on the phosphorylation of
p42/44 or JNK due to LPS stimulation. However, at 50–
200 μg/mL, BFE produced statistically significant (P < 0.05)
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Figure 7: Eﬀects of BFE on IκB degradation in IL-1β-stimulated
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absence of BFE (25–200 μg/mL) for 30 minutes. Cell lysates were
then evaluated for IκB degradation by measuring the amount of
total IκB in cell lysates. Data were analysed using one-way ANOVA
for multiple comparison with post-hoc Student Newman-Keuls
test. ∗P < 0.05 in comparison with IL-1β control.
0
50
100
Phospho-p38
Phospho-JNK
Phospho-p42/44
P
h
os
ph
o-
M
A
P
K
 le
ve
l (
%
 o
f 
LP
S 
co
n
tr
ol
)
∗
∗
∗
+ + + + +
25 50 100 200
LPS (100 ng/mL)
ANE (μg/mL)
−
— —
Figure 8: BFE inhibited p38, but not p42/44 or JNK MAPK in LPS-
stimulated BV-2 microglia. Lysates from LPS-stimulated microglia
were analysed using ELISA for phospho-p38, phospho-42/44, and
phospho-JNK. Data were analysed using one-way ANOVA for
multiple comparison with post-hoc Student Newman-Keuls test.
∗P < 0.05 in comparison with LPS control.
and dose-related inhibition of p38 phosphorylation by
LPS. The p38 MAPK signalling pathway has been widely
reported to activate NF-κB and the subsequent induction
of proinflammatory genes [26–28]. We postulate that BFE
might be exerting an inhibitory action on NF-κB through
p38-dependent action.
4. Conclusions
In this first attempt at elucidating the molecular targets
of anti-inflammatory actions of B. ferruginea, we have
established that an extract of this plant inhibited the pro-
duction of inflammatory cytokines, PGE2 and NO following
inflammatory stimulation. These actions are probably related
to the action of the extract on p38-mediated NF-κB proin-
flammatory gene transcription or IκB-mediated activation
and nuclear translocation NF-κB. These results further
validate the use of B. ferruginea in TAM for treating inflam-
matory conditions. The observed anti-neuroinflammatory
actions of BFE suggest that this plant might be a potential
source of new therapeutic substances for neuroinflam-
matory/neurodegenerative conditions, such as Alzheimer’s
disease. Experiments are in progress to isolate the active
components in this plant.
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